Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse

Validation Efforts Stalled Again

Executive Summary

The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.

You may also be interested in...



Sangamo’s Fabry Gene Therapy Can Rely On 25-Person Registration Trial After US FDA Meeting

With a PRIME designation also in hand for isaralgagene civaparvovec, Sangamo still needs to secure a partner before beginning its pivotal trial, which importantly will not have to include a head-to-head comparison with enzyme replacement therapies.

Sangamo Shoots Up As Regulatory Path Clears For Fabry Gene Therapy

The US group has had a tough year but the signs look more promising for isaralgagene civaparvovec as the FDA agrees on the design for a registrational trial for the gene therapy. Now Sangamo needs to secure a partner.

Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen

Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel